Jeffrey Passer, MD
Nephrology · Omaha, NENPI 1326057571
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $143,058 of the $145,818 with a category attached, or 98.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 98.2% of it on its own, with 22 other manufacturers making up the rest. Among nephrology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $610.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$143K
- Amgen$1K
- Johnson & Johnson$249
- AbbVie$225
- Lilly USA, LLC$173
- Bristol Myers Squibb$158
- plus $737 from 17 others
What the payments were for
- Consulting fees$143,05898%
- Travel & lodging$1170%
- Food & beverage$2,6442%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 71 | $143,174 |
| Amgen | 68 | $1,101 |
| Johnson & Johnson | 18 | $249 |
| AbbVie | 16 | $225 |
| Lilly USA, LLC | 10 | $173 |
| Bristol Myers Squibb | 12 | $158 |
| UCB, Inc. | 8 | $144 |
| GSK | 9 | $119 |
| Mallinckrodt Hospital Products Inc. | 3 | $88 |
| Antares Pharma, Inc. | 3 | $65 |
| Pfizer | 4 | $56 |
| Aurinia Pharma U.S., Inc. | 3 | $47 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Genentech USA, Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AstraZeneca | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $19 |
| Tolmar, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Pacira Therapeutics, Inc. | 1 | $12 |
How this compares
$145,818 in reported general payments places this provider in the 95th percentile of 60 nephrology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 15 | $17,347 |
| EliquisApixaban | 18 | $16,568 |
| Liothyronine Sodium | 133 | $8,146 |
| Testosterone Cypionate | 82 | $5,050 |
| Armour ThyroidThyroid,pork | 71 | $4,922 |
| Np ThyroidThyroid,pork | 62 | $4,827 |
| Hydrocortisone | 21 | $3,447 |
| Testosterone | 17 | $3,040 |
| ProgesteroneProgesterone, Micronized | 79 | $2,394 |
| Fenofibrate | 23 | $1,405 |
| Rosuvastatin Calcium | 90 | $1,200 |
| Ezetimibe | 24 | $1,033 |
| Pantoprazole Sodium | 27 | $967 |
| Levothyroxine Sodium | 145 | $851 |
| Gabapentin | 23 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $12 | $17,34715 claims |
| PfizerEliquis | $56 | $16,56818 claims |
| AbbVieArmour Thyroid | $225 | $4,92271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 nephrology providers in Nebraska.
Other nephrology in Omaha
- Richard LundOmaha$378K
- Roslyn MannonOmaha$64K
- Troy PlumbOmaha$17K
- Eric MagliuloOmaha$9K
- Prasanth RavipatiOmaha$7K
- Joseph BastOmaha$5K
- Stefan HemmingsOmaha$5K
- Sunil JagadeshOmaha$4K
- Judd BauerOmaha$3K
- Mohammed NazmulOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.